Prime Therapeutics LLC v. Omnicare, Inc.

555 F. Supp. 2d 993, 2008 U.S. Dist. LEXIS 41306, 2008 WL 2152207
CourtDistrict Court, D. Minnesota
DecidedMay 21, 2008
DocketCiv. 08-375 (RHK/JSM)
StatusPublished
Cited by1 cases

This text of 555 F. Supp. 2d 993 (Prime Therapeutics LLC v. Omnicare, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Minnesota primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Prime Therapeutics LLC v. Omnicare, Inc., 555 F. Supp. 2d 993, 2008 U.S. Dist. LEXIS 41306, 2008 WL 2152207 (mnd 2008).

Opinion

MEMORANDUM OPINION AND ORDER

RICHARD H. KYLE, District Judge.

INTRODUCTION

Prime Therapeutics LLC (“Prime”) seeks to vacate an arbitration award and Omnicare, Inc. (“Omnicare”) seeks to confirm it. The arbitration involved a contract dispute over the reimbursement of copayments on prescription drugs that were dispensed under the federally funded Medicare Part D program. The arbitrator held that Prime breached the agreement when it failed to reimburse Omnicare for these copayments. For the reasons set forth below, the Court will deny Prime’s motion to vacate the arbitration award and will grant Omnicare’s motion to confirm it.

BACKGROUND

“Enacted in 1965, Medicare is a federally run health insurance program benefit-ting primarily those who are 65 years of age and older.” First Med. Health Plan, Inc. v. Vega-Ramos, 479 F.3d 46, 48 (1st Cir.2007) (citation omitted); see also Matthews v. Leavitt, 452 F.3d 145, 147 n. 1 (2d Cir.2006) (detailing Medicare coverage). In addition, “[e]ach state administers a Medicaid program (with substantial federal funding) to provide medical coverage to its economically disadvantaged population.” Id. In 2003, Congress passed the Medicare Prescription Drug Improvement and Modernization Act, which established a prescription drug benefit program under Medicare Part D to subsidize the out-of-pocket prescription drug costs for individuals eligible for federal assistance. See Pub. L. No. 108-173, 117 Stat. 2066 (2003) (“Part D Plans”). The Medicare Part D program became effective on January 1, 2006, and is administered by the Centers *995 for Medicare and Medicaid Services (“CMS”). (McGrath Aff. Ex. A. at 3; see also 42 U.S.C. § 1395w-101.)

Many enrollees in a Part D Plan are “institutionalized dual eligibles,” -defined as individuals who have Medicare Part D coverage for an entire month, have been “determined eligible by the State” for full Medicaid benefits for the same month, and have been inpatients in a nursing facility, with the stay paid for by Medicaid, throughout the entire month. 42 C.F.R. §§ 423.772, 423.782(a)(2)(ii); see also 42 U.S.C. §§ 1396u-5(c)(6), 1396u-5(a)(2). Their dual enrollment in Medicare and Medicaid exempts them from the “cost-sharing” amounts such as copayments that would otherwise be payable by beneficiaries under a Part D Plan. See 42 C.F.R. § 423.782.

Various health-insurance companies contract with CMS to administer the Part D Plans. (Pl.’s Mem. at 1-2, 6-7.) CMS reimburses the sponsors of Part D Plans who, in turn, pay the pharmacies for the amount of copayments not collected by them from eligible beneficiaries. (Id. 2, 7-8.) Prime is a pharmacy-benefit manager that provides administrative services in processing prescription claims on behalf of health-insurance companies that sponsor the Part D Plans. (Id. at 4.) Omnicare is a pharmacy chain that provides prescription medications to senior citizens in nursing homes and other long-term care facilities. (Id.)

In 2005, Prime and Omnicare entered into a Pharmacy Network Agreement (the “Agreement”). (Doc No. 1 Ex. A.) The parties agreed to comply with all Part D Rules in connection with fulfilling their respective obligations. (Id. § 5.1.) Under the Agreement, Omnicare is required to check with Prime via an on-line system to determine if the individual for whom a prescription is being sought is enrolled under the Part D Plan with Prime and has been identified by CMS as dual-eligible and therefore exempt from having to make a copayment. (Id. §§ 2.5, 2.8.) Prime advises Omnicare via the on-line system as to whether it should charge and collect a copayment. (Id. § 3.) But, in the event Omnicare believes that an individual is or may be eligible for a copayment subsidy, Section 2.5(b) permits Omnicare not to collect a copayment from the individual and to submit a claim for reimbursement after the individual is determined to be eligible for the subsidy. The Agreement also precludes Omnicare from charging an enrollee of the Part D Plan “for products or services that are the responsibility of the Part D Plan Sponsor.” (Id. § 5.3(d).) Finally, if the parties are unable to resolve any dispute arising under the terms of the Agreement, “either party may submit the dispute to binding arbitration ... [and] [t]he arbitrator may determine all questions of law ... [and] has the right to grant permanent and interim damages or injunctive relief....” (Id. § 7.1(b).)

The roll out of the Medicare Part D program was not without operational problems. (Pl.’s Mem. at 9.) Eligibility data from CMS was not always current and consequently would incorrectly reflect that an individual owed a copayment. (Id.) CMS encouraged the pharmacies to fill the prescriptions if the pharmacy believed the individual was eligible. (McGrath Aff. Ex. A at 5.) In 2006, CMS issued instructions to all Part D sponsors for reconciling low-income subsidy status and implementing a Best Available Evidence (“BAE”) policy. (Id.)

With respect to the claims in this arbitration, Prime advised Omnicare that the individuals were ineligible based on the data it had from CMS. (Id. at 3-4.) Omni-care, however, believed that the individuals were eligible and went ahead and dispensed the prescription drug without charging a copayment. (Id.) It then sub *996 mitted these claims to Prime for reimbursement. (Id.) Prime refused to reimburse Omnicare, arguing that Omnicare must support its claim for reimbursement with BAE. (Id.) In May 2007, Omnicare filed a demand for arbitration. (Id. at 1.)

The arbitrator determined that “[although it is Prime’s right and responsibility to initially determine eligibility, Omni has the responsibility under the Agreement not to collect the co-pays in spite of Prime’s denial of eligibility if Omni knows that the enrollee is or may be eligible.” (Id. at 9.) He explained that “pending” the claim—that is, creating receivables rather than charging the patients—was Omni-care’s way of informing Prime that it knew that the individual “is or may be eligible” for not having to pay a copayment. (Id.) He also found that the Agreement did not require Omnicare to provide BAE to Prime in order for Omnicare to be entitled to reimbursement of the copayments. (Id. at 9-11.) Instead, he determined that the sponsors of the Part D Plans, in this case Prime, had the responsibility to provide BAE to CMS. (Id.)

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Stolt-Nielsen SA v. AnimalFeeds International Corp.
548 F.3d 85 (Second Circuit, 2008)

Cite This Page — Counsel Stack

Bluebook (online)
555 F. Supp. 2d 993, 2008 U.S. Dist. LEXIS 41306, 2008 WL 2152207, Counsel Stack Legal Research, https://law.counselstack.com/opinion/prime-therapeutics-llc-v-omnicare-inc-mnd-2008.